

Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 04:41PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

HAEMATOTOLOGY

PROTHROMBIN TIME STUDIES (PT/INR)

PT TEST (PATIENT) by PHOTO OPTICAL CLOT DETECTION	14.2	SECS	11.5 - 14.5
PT (CONTROL) by PHOTO OPTICAL CLOT DETECTION	12	SECS	
ISI by PHOTO OPTICAL CLOT DETECTION	1.1		
INTERNATIONAL NORMALISED RATIO (INR) by PHOTO OPTICAL CLOT DETECTION	1.2		0.80 - 1.20
PT INDEX by PHOTO OPTICAL CLOT DETECTION	84.51	%	

INTERPRETATION:-

1. INR is the parameter of choice in monitoring adequacy of oral anti-coagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity.
2. Prolonged INR suggests potential bleeding disorder /bleeding complications
3. Results should be clinically correlated.
4. Test conducted on Citrated Plasma

RECOMMENDED THERAPEUTIC RANGE FOR ORAL ANTI-COAGULANT THERAPY (INR)

INDICATION		INTERNATIONAL NORMALIZED RATIO (INR)
Treatment of venous thrombosis	Low Intensity	2.0 - 3.0
Treatment of pulmonary embolism		
Prevention of systemic embolism in tissue heart valves		
Valvular heart disease		
Acute myocardial infarction		
Atrial fibrillation		
Bileaflet mechanical valve in aortic position		
Recurrent embolism	High Intensity	2.5 - 3.5
Mechanical heart valve		




DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 04:41PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
Antiphospholipid antibodies ⁺			

COMMENTS:

The prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) are measures of the efficacy of the extrinsic pathway of coagulation. PT test reflects the adequacy of factors I (fibrinogen), II (prothrombin), V, VII, and X. It is used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway.

The common causes of prolonged prothrombin time are :

- 1.Oral Anticoagulant therapy.
- 2.Liver disease.
- 3.Vit K. deficiency.
- 4.Disseminated intra vascular coagulation.
- 5.Factor 5, 7 , 10 or Prothrombin deficiency




DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS , MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 06:39PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CLINICAL CHEMISTRY/BIOCHEMISTRY

FERRITIN

FERRITIN: SERUM	221.07	ng/mL	21.81 - 274.66
-----------------	--------	-------	----------------

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

INTERPRETATION:

Serum ferritin appears to be in equilibrium with tissue ferritin and is a good indicator of storage iron in normal subjects and in most disorders. In patients with some hepatocellular diseases, malignancies and inflammatory diseases, serum ferritin is a disproportionately high estimate of storage iron because serum ferritin is an acute phase reactant. In such disorders iron deficiency anemia may exist with a normal serum ferritin concentration. In the presence of inflammation, persons with low serum ferritin are likely to respond to iron therapy.

DECREASED:

1. Iron depletion appears to be the only condition associated with reduced serum ferritin concentrations.
2. Hypothyroidism.
3. Vitamin-C deficiency.

INCREASED FERRITIN DUE TO IRON OVERLOAD (PRIMARY):

1. Hemochromatosis or hemosiderosis.
2. Wilson Disease.

INCREASED FERRITIN DUE TO IRON OVERLOAD (SECONDARY):

1. Transfusion overload
2. Excess dietary Iron
3. Porphyria Cutanea tarda
4. Ineffective erythropoiesis.


INCREASED FERRITIN WITHOUT IRON OVERLOAD:


1. Liver disorders (NASH) or viral hepatitis (B/C).
2. Inflammatory conditions (Ferritin is a acute phase reactant) both acute and chronic.
3. Leukaemia, hodgekin's disease.
4. Alcohol excess.
5. Other malignancies in which increases probably reflect the escape of ferritin from damaged liver cells, impaired clearance from the plasma, synthesis of ferritin by tumour cells.
6. Ferritin levels below 10 ng/ml have been reported as indicative of iron deficiency anemia.

NOTE:

1. As Ferritin is an acute phase reactant, it is often raised in both acute and chronic inflammatory condition of the body such as infections leading to false positive results. It can therefore mask a diagnostically low result. In such Cases serum ferritin levels should always be correlated with C-Reactive proteins to rule out any inflammatory conditions.
2. Patients with iron deficiency anaemia may occasionally have elevated or normal ferritin levels. This is usually seen in patients already receiving iron therapy or in patients with concomitant hepatocellular injury.




DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 13/Dec/2024 09:38AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

AMMONIA (NH3)

AMMONIA (NH3): BLOOD	56	µg/dL	27 - 90
by ENZYMATIC - GLDH, SPECTROPHOTOMETRY			

INTERPRETATION:

Ammonia is elevated in the following condition:

1. Liver disease
2. urinary tract infection with distention and stasis
3. Reye syndrome
4. inborn errors of metabolism including deficiency of enzymes in the urea cycle
5. HHH syndrome (hyperammonemia - homocitrullinuria, hyperornithinemia)
6. Some normal neonates (usually returning to normal in 48 hours)
7. Total parenteral nutrition
8. Ureterosigmoidostomy
9. Sodium valproate therapy.
10. Ammonia determination is indicated in neonates with neurological deterioration, subjects with lethargy and/or emesis not explained, and in patients with possible encephalopathy.
11. Ammonia measurements are mainly of use in the diagnosis of urea cycle deficiencies (any neonate with unexplained nausea, vomiting, or neurological deterioration appearing after first feeding)




DR. VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR. YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 07:38PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

TUMOUR MARKER

ALPHA FETO PROTEIN (AFP): TUMOR MARKER

ALPHA FETO PROTEIN (AFP) 3.227 ng/mL 0.0 - 10.0

TUMOUR MARKER: SERUM

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

INTERPRETATION:

1. Alpha-fetoprotein (AFP) is a glycoprotein that is produced in early fetal life by the liver, GIT & yolk sac and by a variety of tumors including hepatocellular carcinoma, hepatoblastoma, and nonseminomatous germ cell tumors of the ovary and testis (eg, yolk sac and embryonal carcinoma). Most studies report elevated AFP concentrations in approximately 70% of patients with hepatocellular carcinoma. Elevated AFP concentrations are found in 50% to 70% of patients with non seminomatous testicular tumors.
2. It is a major component of fetal plasma, reaching a peak concentration of 3mg/mL at 12 weeks of gestation. Following birth, it clears from circulation, falling to 100 ng/ mL by 150 days and reaching adult values by end of 1 year.
3. AFP is elevated during pregnancy. Persistence of AFP in the mother following birth is a rare hereditary condition.
3. Neonates have markedly elevated AFP levels (>100,000 ng/mL) that rapidly fall to below 100 ng/mL by 150 days and gradually return to normal over their first year.
4. Concentrations of AFP above the reference range also have been found in serum of patients with benign liver disease (eg, viral hepatitis, cirrhosis), gastrointestinal tract tumors and, along with carcinoembryonic antigen in ataxia telangiectasia.

CAUTION:

1. It is not recommended to use this assay for the initial diagnosis of the above mentioned malignancies.
2. It is best used for monitoring of therapy and to look for relapse of malignancies that have been surgically excised or cleared with chemo/radiotherapy.
3. Failure of the AFP value to return to normal by approximately 1 month after surgery suggests the presence of residual tumor.
4. Elevation of AFP after remission suggests tumor recurrence; however, tumors originally producing AFP may recur without an increase in AFP.

NOTE:

A difference of > 20% between two measurements is considered to be medically significant. The assay is used only as an adjunct to diagnosis and monitoring/ diagnosis should be confirmed by other tests/procedures.





DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)



DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 06:39PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL

PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL: 3.42 ng/mL 0.0 - 4.0
 SERUM
 by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)

INTERPRETATION:

NOTE:

1. This is a recommended test for detection of prostate cancer along with Digital Rectal Examination (DRE) in males above 50 years of age.
2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
3. PSA levels may appear consistently elevated / depressed due to the interference by heterophilic antibodies & nonspecific protein binding
4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massage, indwelling catheterization, ultrasonography and needle biopsy of prostate is not recommended as they falsely elevate levels
5. PSA values regardless of levels should not be interpreted as absolute evidence of the presence or absence of disease. All values should be correlated with clinical findings and results of other investigations
6. Sites of Non-prostatic PSA production are breast epithelium, salivary glands, peri-urethral & anal glands, cells of male urethra & breast milk
7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity
8. The concentration of PSA in a given specimen, determined with assays from different manufacturers, may not be comparable due to differences in assay methods, calibration, and reagent specificity.

RECOMMENDED TESTING INTERVALS

1. Preoperatively (Baseline)
2. 2-4 Days Post operatively
3. Prior to discharge from hospital
4. Monthly Follow Up if levels are high and showing a rising trend

POST SURGERY	FREQUENCY OF TESTING
1st Year	Every 3 Months
2 nd Year	Every 4 Months
3 rd Year Onwards	Every 6 Months

CLINICAL USE:

1. An aid in the early detection of Prostate cancer when used in conjunction with Digital rectal examination in males more than 50 years of age and in those with two or more affected first degree relatives.
2. Followup and management of Prostate cancer patients.
3. Detect metastatic or persistent disease in patients following surgical or medical treatment of Prostate cancer

INCREASED LEVEL:

1. Prostate cancer
2. Benign Prostatic Hyperplasia
3. Prostatitis
4. Genitourinary infections




 DR. VINAY CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR. YUGAM CHOPRA

CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME : Mr. RAJAT JAIN
AGE/ GENDER : 37 YRS/MALE
COLLECTED BY :
REFERRED BY : CENTRAL PHOENIX CLUB (AMBALA CANTT)
BARCODE NO. : 01522361
CLIENT CODE. : KOS DIAGNOSTIC LAB
CLIENT ADDRESS : 6349/1, NICHOLSON ROAD, AMBALA CANTT

PATIENT ID : 1697583
REG. NO./LAB NO. : 012412120033
REGISTRATION DATE : 12/Dec/2024 04:08 PM
COLLECTION DATE : 12/Dec/2024 04:13PM
REPORTING DATE : 12/Dec/2024 05:42PM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CLINICAL PATHOLOGY

URINE ROUTINE & MICROSCOPIC EXAMINATION

PHYSICAL EXAMINATION

QUANTITY RECIEVED <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	10	ml	
COLOUR <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	PALE YELLOW		PALE YELLOW
TRANSPARANCY <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	HAZY		CLEAR
SPECIFIC GRAVITY <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	>=1.030		1.002 - 1.030

CHEMICAL EXAMINATION

REACTION <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	ACIDIC		
PROTEIN <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Negative		NEGATIVE (-ve)
SUGAR <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Negative		NEGATIVE (-ve)
pH <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	5.5		5.0 - 7.5
BILIRUBIN <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Negative		NEGATIVE (-ve)
NITRITE <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Negative		NEGATIVE (-ve)
UROBILINOGEN <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Normal	EU/dL	0.2 - 1.0
KETONE BODIES <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	Negative		NEGATIVE (-ve)
BLOOD <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	TRACE		NEGATIVE (-ve)
ASCORBIC ACID <small>by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY</small>	NEGATIVE (-ve)		NEGATIVE (-ve)

MICROSCOPIC EXAMINATION

RED BLOOD CELLS (RBCs)	3-4	/HPF	0 - 3
------------------------	-----	------	-------




DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)



Dr. Vinay Chopra
 MD (Pathology & Microbiology)
 Chairman & Consultant Pathologist

Dr. Yugam Chopra
 MD (Pathology)
 CEO & Consultant Pathologist

NAME	: Mr. RAJAT JAIN	PATIENT ID	: 1697583
AGE/ GENDER	: 37 YRS/MALE	REG. NO./LAB NO.	: 012412120033
COLLECTED BY	:	REGISTRATION DATE	: 12/Dec/2024 04:08 PM
REFERRED BY	: CENTRAL PHOENIX CLUB (AMBALA CANTT)	COLLECTION DATE	: 12/Dec/2024 04:13PM
BARCODE NO.	: 01522361	REPORTING DATE	: 12/Dec/2024 05:42PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
PUS CELLS	15-20	/HPF	0 - 5
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
EPITHELIAL CELLS	1-3	/HPF	ABSENT
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
CRYSTALS	NEGATIVE (-ve)		NEGATIVE (-ve)
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
CASTS	NEGATIVE (-ve)		NEGATIVE (-ve)
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
BACTERIA	NEGATIVE (-ve)		NEGATIVE (-ve)
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
OTHERS	NEGATIVE (-ve)		NEGATIVE (-ve)
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			
TRICHOMONAS VAGINALIS (PROTOZOA)	ABSENT		ABSENT
by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT			

*** End Of Report ***




 DR.VINAY CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY & MICROBIOLOGY)


 DR.YUGAM CHOPRA
 CONSULTANT PATHOLOGIST
 MBBS, MD (PATHOLOGY)

